organization · Reporting owner
Cactus Healthcare Management LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cactus Acquisition Corp. 1 LtdCCTS · Entity 88589 | 10% owner | February 23, 2024 | February 27, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cactus Acquisition Corp. 1 Ltd
Report date February 23, 2024 · Filed February 27, 2024
Jointly reported with Cactus Healthcare Management LP
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A ordinary sharesSEC Table I · non-derivative | Direct | 632,501 |
Reported balance
After 2024-02-23 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-02-23 · Sale · Disposed 2,530,000 · Balance 632,501 F1: The transaction reported herein consists of the private sale by Cactus Healthcare Management LP of (i) 2,530,000 founders shares (consisting of 2,529,999 Class A ordinary shares and one Class B ordinary share which may be converted into a Class A ordinary share upon election by the holder thereof, and therefore treated for purposes hereof as a Class A ordinary share) and (ii) 3,893,334 warrants to purchase Class A ordinary shares. F2: The aggregate sales price received by the reporting persons for all securities sold in the transaction (the founders shares and the warrants) reported herein was $1.00, which is an effective price of less than $0.00 (i) per share and (ii) per warrant. F3: The securities reported in this row are held of record by Cactus Healthcare Management LP (the "Cactus sponsor"). Cactus Healthcare Management LLC (the "Cactus sponsor GP") serves as the sole general partner of the Cactus sponsor and directs voting and investment decisions made by the Cactus sponsor with respect to the subject shares. The Cactus sponsor GP is owned equally by Hibotan LLC (an affiliate of Israel Biotech Fund), Kalistcare Limited (an affiliate of Consensus Business Group) and Clal Biotechnology Industries Cactus Ltd. (an affiliate of Clal Biotechnology Industries Ltd.), each of which holds a 33.33% equity interest in the Cactus sponsor GP. The Cactus sponsor GP does not possess a pecuniary interest with respect to the subject shares and therefore disclaims beneficial ownership thereof. |
| Warrants to purchase Class A ordinary sharesSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 | Direct | 973,333 |
Reported balance
After 2024-02-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-23 · Sale · Disposed 3,893,334 · Balance 973,333 F1: The transaction reported herein consists of the private sale by Cactus Healthcare Management LP of (i) 2,530,000 founders shares (consisting of 2,529,999 Class A ordinary shares and one Class B ordinary share which may be converted into a Class A ordinary share upon election by the holder thereof, and therefore treated for purposes hereof as a Class A ordinary share) and (ii) 3,893,334 warrants to purchase Class A ordinary shares. F2: The aggregate sales price received by the reporting persons for all securities sold in the transaction (the founders shares and the warrants) reported herein was $1.00, which is an effective price of less than $0.00 (i) per share and (ii) per warrant. F4: The warrants become exercisable 30 days after the Issuer completes its initial business combination (which date is not known currently). F5: The warrants expire on the 5th year anniversary of the Issuer's initial business combination (which date is not known currently). F3: The securities reported in this row are held of record by Cactus Healthcare Management LP (the "Cactus sponsor"). Cactus Healthcare Management LLC (the "Cactus sponsor GP") serves as the sole general partner of the Cactus sponsor and directs voting and investment decisions made by the Cactus sponsor with respect to the subject shares. The Cactus sponsor GP is owned equally by Hibotan LLC (an affiliate of Israel Biotech Fund), Kalistcare Limited (an affiliate of Consensus Business Group) and Clal Biotechnology Industries Cactus Ltd. (an affiliate of Clal Biotechnology Industries Ltd.), each of which holds a 33.33% equity interest in the Cactus sponsor GP. The Cactus sponsor GP does not possess a pecuniary interest with respect to the subject shares and therefore disclaims beneficial ownership thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported herein consists of the private sale by Cactus Healthcare Management LP of (i) 2,530,000 founders shares (consisting of 2,529,999 Class A ordinary shares and one Class B ordinary share which may be converted into a Class A ordinary share upon election by the holder thereof, and therefore treated for purposes hereof as a Class A ordinary share) and (ii) 3,893,334 warrants to purchase Class A ordinary shares.
F2: The aggregate sales price received by the reporting persons for all securities sold in the transaction (the founders shares and the warrants) reported herein was $1.00, which is an effective price of less than $0.00 (i) per share and (ii) per warrant.
F3: The securities reported in this row are held of record by Cactus Healthcare Management LP (the "Cactus sponsor"). Cactus Healthcare Management LLC (the "Cactus sponsor GP") serves as the sole general partner of the Cactus sponsor and directs voting and investment decisions made by the Cactus sponsor with respect to the subject shares. The Cactus sponsor GP is owned equally by Hibotan LLC (an affiliate of Israel Biotech Fund), Kalistcare Limited (an affiliate of Consensus Business Group) and Clal Biotechnology Industries Cactus Ltd. (an affiliate of Clal Biotechnology Industries Ltd.), each of which holds a 33.33% equity interest in the Cactus sponsor GP. The Cactus sponsor GP does not possess a pecuniary interest with respect to the subject shares and therefore disclaims beneficial ownership thereof.
F4: The warrants become exercisable 30 days after the Issuer completes its initial business combination (which date is not known currently).
F5: The warrants expire on the 5th year anniversary of the Issuer's initial business combination (which date is not known currently).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 23, 2024 Filed Feb 27, 2024 20:27 UTC | Cactus Acquisition Corp. 1 Ltd CCTS · Entity 88589 | SaleWarrants to purchase Class A ordinary shares · Derivative | 3,893,334 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001213900-24-017449 · ownership.xml · derivative · entry 2 Cactus Healthcare Management LP · CIK 0001918110 · 10% owner Cactus Healthcare Management LLC · CIK 0001918130 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 973,333 Underlying: Class A ordinary shares · 3,893,334 shares Expires not disclosed F1 · kind: The transaction reported herein consists of the private sale by Cactus Healthcare Management LP of (i) 2,530,000 founders shares (consisting of 2,529,999 Class A ordinary shares and one Class B ordinary share which may be converted into a Class A ordinary share upon election by the holder thereof, and therefore treated for purposes hereof as a Class A ordinary share) and (ii) 3,893,334 warrants to purchase Class A ordinary shares. F2 · price: The aggregate sales price received by the reporting persons for all securities sold in the transaction (the founders shares and the warrants) reported herein was $1.00, which is an effective price of less than $0.00 (i) per share and (ii) per warrant. F4 · derivative.exercise_date: The warrants become exercisable 30 days after the Issuer completes its initial business combination (which date is not known currently). F5 · derivative.expiration_date: The warrants expire on the 5th year anniversary of the Issuer's initial business combination (which date is not known currently). F3 · ownership.direct: The securities reported in this row are held of record by Cactus Healthcare Management LP (the "Cactus sponsor"). Cactus Healthcare Management LLC (the "Cactus sponsor GP") serves as the sole general partner of the Cactus sponsor and directs voting and investment decisions made by the Cactus sponsor with respect to the subject shares. The Cactus sponsor GP is owned equally by Hibotan LLC (an affiliate of Israel Biotech Fund), Kalistcare Limited (an affiliate of Consensus Business Group) and Clal Biotechnology Industries Cactus Ltd. (an affiliate of Clal Biotechnology Industries Ltd.), each of which holds a 33.33% equity interest in the Cactus sponsor GP. The Cactus sponsor GP does not possess a pecuniary interest with respect to the subject shares and therefore disclaims beneficial ownership thereof. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 20:27 UTC | Cactus Acquisition Corp. 1 Ltd CCTS · Entity 88589 | SaleClass A ordinary shares | 2,530,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-017449 · ownership.xml · nonDerivative · entry 1 Cactus Healthcare Management LP · CIK 0001918110 · 10% owner Cactus Healthcare Management LLC · CIK 0001918130 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 632,501 F1 · kind: The transaction reported herein consists of the private sale by Cactus Healthcare Management LP of (i) 2,530,000 founders shares (consisting of 2,529,999 Class A ordinary shares and one Class B ordinary share which may be converted into a Class A ordinary share upon election by the holder thereof, and therefore treated for purposes hereof as a Class A ordinary share) and (ii) 3,893,334 warrants to purchase Class A ordinary shares. F2 · price: The aggregate sales price received by the reporting persons for all securities sold in the transaction (the founders shares and the warrants) reported herein was $1.00, which is an effective price of less than $0.00 (i) per share and (ii) per warrant. F3 · ownership.direct: The securities reported in this row are held of record by Cactus Healthcare Management LP (the "Cactus sponsor"). Cactus Healthcare Management LLC (the "Cactus sponsor GP") serves as the sole general partner of the Cactus sponsor and directs voting and investment decisions made by the Cactus sponsor with respect to the subject shares. The Cactus sponsor GP is owned equally by Hibotan LLC (an affiliate of Israel Biotech Fund), Kalistcare Limited (an affiliate of Consensus Business Group) and Clal Biotechnology Industries Cactus Ltd. (an affiliate of Clal Biotechnology Industries Ltd.), each of which holds a 33.33% equity interest in the Cactus sponsor GP. The Cactus sponsor GP does not possess a pecuniary interest with respect to the subject shares and therefore disclaims beneficial ownership thereof. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.